ProQR Therapeutics N.V.

NASDAQ:PRQR

2.67 (USD) • At close December 24, 2024
Bedrijfsnaam ProQR Therapeutics N.V.
Symbool PRQR
Munteenheid USD
Prijs 2.67
Beurswaarde 275,554,680
Dividendpercentage 0%
52-weken bereik 1.61 - 4.62
Industrie Biotechnology
Sector Healthcare
CEO Mr. Daniel Anton de Boer
Website https://www.proqr.com

An error occurred while fetching data.

Over ProQR Therapeutics N.V.

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial

Vergelijkbare Aandelen

MiNK Therapeutics, Inc. logo

MiNK Therapeutics, Inc.

INKT

0.529 USD

BeyondSpring Inc. logo

BeyondSpring Inc.

BYSI

1.69 USD

Sera Prognostics, Inc. logo

Sera Prognostics, Inc.

SERA

7.95 USD

Corvus Pharmaceuticals, Inc. logo

Corvus Pharmaceuticals, Inc.

CRVS

4.9 USD

Syros Pharmaceuticals, Inc. logo

Syros Pharmaceuticals, Inc.

SYRS

0.203 USD

Freeline Therapeutics Holdings plc logo

Freeline Therapeutics Holdings plc

FRLN

6.49 USD

Catalyst Biosciences, Inc. logo

Catalyst Biosciences, Inc.

CBIO

0.511 USD

BioSig Technologies, Inc. logo

BioSig Technologies, Inc.

BSGM

1.48 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)